Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman EM. Remington GM, et al. Among authors: racke mk. Ther Adv Neurol Disord. 2010 Jan;3(1):3-13. doi: 10.1177/1756285609355851. Ther Adv Neurol Disord. 2010. PMID: 21180632 Free PMC article.
Mycophenolate mofetil in multiple sclerosis.
Frohman EM, Brannon K, Racke MK, Hawker K. Frohman EM, et al. Among authors: racke mk. Clin Neuropharmacol. 2004 Mar-Apr;27(2):80-3. doi: 10.1097/00002826-200403000-00006. Clin Neuropharmacol. 2004. PMID: 15252268
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R. Frohman EM, et al. Among authors: racke mk. Ther Adv Neurol Disord. 2010 Jan;3(1):15-28. doi: 10.1177/1756285609353354. Ther Adv Neurol Disord. 2010. PMID: 21180633 Free PMC article.
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: racke mk. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
Multiple sclerosis--the plaque and its pathogenesis.
Frohman EM, Racke MK, Raine CS. Frohman EM, et al. Among authors: racke mk. N Engl J Med. 2006 Mar 2;354(9):942-55. doi: 10.1056/NEJMra052130. N Engl J Med. 2006. PMID: 16510748 Review. No abstract available.
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.
Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL. Harp CT, et al. Among authors: racke mk. Eur J Immunol. 2010 Oct;40(10):2942-56. doi: 10.1002/eji.201040516. Eur J Immunol. 2010. PMID: 20812237 Free PMC article.
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.
Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E. Greenberg BM, et al. Among authors: racke mk. JAMA Neurol. 2013 Feb;70(2):248-51. doi: 10.1001/jamaneurol.2013.1017. JAMA Neurol. 2013. PMID: 23530268 No abstract available.
200 results